Treace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings Results

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) issued its earnings results on Thursday. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.06, Zacks reports. The firm had revenue of $52.57 million during the quarter, compared to analyst estimates of $52.07 million. Treace Medical Concepts had a negative net margin of 30.33% and a negative return on equity of 51.12%. The company's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.30) earnings per share. Treace Medical Concepts updated its FY 2025 guidance to EPS.

Treace Medical Concepts Price Performance

TMCI traded down $0.71 on Friday, reaching $6.83. The company had a trading volume of 2,354,436 shares, compared to its average volume of 680,453. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.12. Treace Medical Concepts has a 52-week low of $4.29 and a 52-week high of $10.79. The company has a market cap of $429.54 million, a price-to-earnings ratio of -6.90 and a beta of 0.79. The business has a 50 day simple moving average of $7.57 and a 200 day simple moving average of $7.94.

Insider Transactions at Treace Medical Concepts

In related news, insider Sean F. Scanlan sold 50,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $7.97, for a total transaction of $398,500.00. Following the transaction, the insider now directly owns 364,081 shares of the company's stock, valued at approximately $2,901,725.57. This trade represents a 12.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 27.72% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Truist Financial decreased their price objective on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. UBS Group reduced their price objective on shares of Treace Medical Concepts from $10.00 to $8.60 and set a "neutral" rating for the company in a research note on Friday. Finally, BTIG Research raised shares of Treace Medical Concepts from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a report on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $10.16.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.